All In MedTech

Device Trial Radar · NCT07889388

RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes Study

Evaluation of the Effectiveness and Safety of the RIGHTEST™ iFree 2 Continuous Glucose Monitoring System in Pregnant Women With Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Jun 9, 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Bionime CorporationNot on our public-company list
Sponsor type
Industry
First posted
Oct 22, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the accuracy and safety of the RIGHTEST iFree 2 Continuous Glucose Monitoring (CGM) System in pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes. The system uses a small sensor placed under the skin to measure glucose levels in the fluid between cells. Approximately 104 women will participate at study sites in Germany and Taiwan. Each participant will wear two sensors, one on each upper arm, for up to 15 days. During one clinic visit lasting up to six hours, blood samples will be collected every 15 minutes. Sensor readings will be compared with laboratory blood glucose measurements to assess accuracy. Participants will also be assessed for side effects, including skin reactions at the sensor sites, and will receive a safety follow-up after sensor removal. No procedures will be used to deliberately raise or lower blood glucose levels.

Conditions

  • Diabetes Mellitus, Type 1 Diabetes
  • Diabetes Mellitus, Type 2
  • Diabetes, Gestational

Interventions

  • RIGHTEST iFree 2 Continuous Glucose Monitoring SystemDevice

    The RIGHTEST iFree 2 Continuous Glucose Monitoring System (Bionime Corporation) measures interstitial glucose continuously for up to 15 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of CGM Readings Within ±20% of Reference Blood Glucose MeasurementsTime frame: During one sampling session of up to 6 hours on Day 1, Day 5 ±1, Day 10 ±1, or Day 15 of sensor wear.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm

    Ulm, Baden-Wurttemberg, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.